News & Announcements

The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine Daclatasvir

The Medicines Patent Pool Statement on US Food and Drug Administration Approval of Tenofovir Alafenamide (TAF) Single Tablet Regimen

The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment

Upcoming events

29 November – 4 December 2015

18th ICASA
Harare, Zimbabwe


Recent Highlights

Expressions of Interest – Daclatasvir

MPP now invites Expressions of Interest from potential sub-licensees for licence to manufacture and sell formulations containing daclatasvir (DCV) in the respective Territory.
Instructions available on the Expression of Interest page

New agreements for TAF signed with Lupin and Micro Labs

View our sub-licensees section

Ensuring new medicines reach those in most need

Read MPP’s Executive Director, Greg Perry and Head of Policy, Esteban Burrone comment published in the latest issue of The Lancet HIV

ARV forcasts presented at IAS 2015

Forecasted demand for current and new ARV medicines in low- and middle-income countries, 2014-2025

UNITAID and MPP publish ARV Snapshot Report

See the report